R-Pdf/Gbb 0.01% gel
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Burns
Conditions
Burns, Electric Burns
Trial Timeline
Jul 1, 2011 → Apr 1, 2012
NCT ID
NCT00812513About R-Pdf/Gbb 0.01% gel
R-Pdf/Gbb 0.01% gel is a phase 2 stage product being developed by Johnson & Johnson for Burns. The current trial status is unknown. This product is registered under clinical trial identifier NCT00812513. Target conditions include Burns, Electric Burns.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00812513 | Phase 2 | UNKNOWN |
Competing Products
12 competing products in Burns
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ceftolozane/tazobactam | Merck | Approved | 85 |
| linezolid | Pfizer | Phase 1 | 32 |
| Somatropin + 0.09% Saline Solution | Pfizer | Phase 2/3 | 64 |
| Ciprofloxacin (BAYO9867) + Ciprofloxacin (BAYO9867) | Bayer | Phase 3 | 74 |
| cP12 | United Therapeutics | Phase 2 | 49 |
| cNP8 | United Therapeutics | Phase 1 | 30 |
| Sulfamylon® For 5 % Topical Solution + Topical Antimicrobial/Antifungal Medications | Viatris | Approved | 82 |
| Sheet skin grafts affixed with Fibrin Sealant (lyophilized) with 4 IU/mL Thrombin | Baxter | Phase 1/2 | 38 |
| I-020502 | Baxter | Phase 2 | 49 |
| Pathogen-Reduced Plasma + Crystalloid Solutions | Cerus | Approved | 77 |
| NexoBrid + Gel Vehicle | MediWound | Phase 3 | 69 |
| NexoBrid | MediWound | Phase 3 | 69 |